新的血液测试可能会预测三至四年内阿尔茨海默氏症的发病, 但对于健康的人来说尚不可靠。 A new blood test may predict Alzheimer’s onset within 3–4 years, but isn’t yet reliable for healthy people.

测量p-tau217蛋白质的血液测试显示,根据对600多名老年人的研究,在3至4年的窗口内预测阿尔茨海默氏症的发病有希望。 A blood test measuring p-tau217 protein shows promise in predicting Alzheimer’s symptom onset within a three- to four-year window, years before signs appear, based on a study of over 600 older adults. 这项检测能检测与阿尔茨海默病相关的早期脑部变化, 检测的方法不那么侵袭性, 并且比扫描或脊柱抽插更便宜, 两种版本已经获得FDA的批准, The test, which detects early brain changes linked to Alzheimer’s, is less invasive and cheaper than scans or spinal taps, and two versions are already FDA-approved for symptomatic patients. 然而,专家们警告说,对于健康的个人来说,由于肾病或肥胖等条件的变异,它尚不可靠,结果对于退休等个人决定而言仍然太不确定。 However, experts caution it’s not yet reliable for healthy individuals due to variability from conditions like kidney disease or obesity, and results remain too uncertain for personal decisions like retirement. 虽然该工具可以帮助预防性治疗临床试验,但更广泛的使用取决于进一步验证和经证明的改善结果的干预措施。 While the tool could aid clinical trials for preventive treatments, broader use depends on further validation and proven interventions that improve outcomes.